November 9, 2014 |
Women, racial minorities, and people over 75 are underrepresented in the clinical trials that help determine the way all cardiac patients are treated, a study from Lankenau Medical Center researchers has found. This means that the recommendations that doctors use to treat heart problems may not be the best for all groups, said senior author Peter Kowey, head of Cardiology for Main Line Health. A team at Lankenau Heart Institute and Lankenau Institute for Medical Research laid out the disparities in a research letter published online by the Journal of the American Medical Association.
October 8, 2014 |
More than a decade after prostate cancer became the economic driver behind proton beam therapy in the U.S., it still isn't clear that men treated with the technology do better than those who get less costly radiation treatments. That's why expert groups have recently advised against insurance coverage of proton therapy for prostate cancer - and why some private plans are refusing to pay for it. The Catch-22 is that this pullback is hampering a clinical trial co-led by the University of Pennsylvania that would finally settle the question of superiority.
September 15, 2014 |
For the eight years since her diagnosis in 2006, drugs, surgery, and chemotherapy had kept Debra Hinkle's breast cancer at bay. But now, the conventional treatments were failing, and the disease was spreading. So when her oncologist decided it was time for the Bucks County woman to consider relatively untested therapies, she was more than willing. "I thought that if I didn't do a clinical trial now, maybe I wouldn't be able to later," said Hinkle, 54, who lives in Newtown Township and works as a software-development project manager.
June 19, 2014 |
Taxes, takeovers, and preschoolers are the topics of the moment with drugmaker Shire P.L.C., whose closing stock price reached an all-time high Monday. With official headquarters in low-tax Ireland and operations in Wayne, Exton, and Lexington, Mass., Shire is the subject of takeover speculation. That's largely due to a recent trend of health-care companies trying to buy smaller outfits registered in Ireland and other countries to avoid higher U.S. corporate taxes, a move known as a tax inversion.
June 13, 2014 |
A Fort Washington woman is embarking on a 27-day hike to raise money and awareness about progeria, an extremely rare genetic mutation that causes premature aging and death. Amy Ruhf began planning the trip soon after meeting Phyllis Falcone, a fellow member of First Presbyterian Church of Ambler and the mother of two young boys with progeria. Nathan, 8, and Bennett, 5, are part of a clinical trial of a drug that may help slow the disease's progression. Their father said the treatment appears to be helping, but it is still taking a toll on their young bodies.
March 9, 2014 |
With surgery and chemotherapy, Roberta Bash, 67, of Downingtown beat advanced-stage ovarian cancer in 2010. Then, it came back. "Cancer can go dormant, and I didn't know that," she said. The second time, Bash wanted to explore all her options - including an experimental treatment at Penn Medicine that manipulates a patient's tumor cells to trigger an immune response. So, during her surgery last March, instead of allowing her tumor to be tossed out or donated for research, she saved it. The company StoreMyTumor, which markets itself as a concierge service for tumors, negotiated the tissue's harvest, processing, and cryopreservation.
September 23, 2013 |
Evelyn Boss Cogan, 65, a professor at La Salle University, died Saturday, Sept. 14, of lung cancer at her home in Center City. Known to friends as Evie, she fought an eight-year battle with cancer and chronicled the experience in a 2013 article for Philadelphia Lawyer magazine. It started in 2005 with a bad cough, she wrote. After cancer was found in her right lung, a doctor told her to go home and get her affairs in order; she had six months to live. Undaunted, she sought out Corey Langer, a doctor at Fox Chase Cancer Center, who scheduled chemotherapy, radiation, and more chemo.
October 14, 2012 |
In a significant departure from industry practice, GlaxoSmithKline P.L.C., said it would make available to outside researchers the raw but anonymous patient data from clinical trials for drugs it has developed or discontinued, and its tuberculosis compound library. Pharmaceutical companies generally don't divulge such information, claiming that it is a proprietary secret. "As a truly global health care company, I believe we have a responsibility to do all we can at GSK to use our resources, knowledge and expertise to help tackle serious global health challenges," Glaxo chief executive Andrew Witty said in a statement.
November 3, 2010 |
All eyes may be on General Motors Co.'s efforts to drive 365 million shares into the hands of the public at a guesstimated $26 to $29 per share in an initial public offering. But a much smaller pending IPO for a Philadelphia-area life-sciences firm caught my attention. If Cutanea Life Sciences Inc. succeeds in selling 2.3 million shares for between $6 and $7 per share, it would be the third IPO for a Philadelphia-area health-care company in 2010. Based in Malvern, Cutanea is a virtual company that in-licenses compounds from other companies.
July 19, 2010
Wayne-based Encorium Group Inc., which runs clinical trials and patient registries for pharmaceutical companies, announced today that it has acquired Swiss-based Progenitor Holdings AG, for euro 1.7 million (about $2.2 million). Progenitor has wholly owned subsidiaries in Mexico, Panama, Argentina, Chile, Switzerland, India and Hong Kong. Encorium said in a statement that the acquisition would give it access clinical trials being conducted in such emerging markets as Latin America, India and the Asia Pacific region.